Institution · Rigel (United States)
Most cited papers from Rigel (United States)
What are the most cited papers from Rigel (United States)?
The most cited paper from Rigel (United States) is "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia" (Jonathan W. Friedberg, Jeff Porter Sharman, John William Sweetenham et al., 2009), with 747 citations. Next come "MAPKK-Independent Activation of p38α Mediated by TAB1-Dependent Autophosphorylation of p38α" (535) and "R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation" (520).
Showing 50 of 60 papers. Every paper with more than 61 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Jonathan W. Friedberg, Jeff Porter Sharman, John William Sweetenham et al. · Blood | 18 Nov 2009 | 747 |
| 2 | MAPKK-Independent Activation of p38α Mediated by TAB1-Dependent Autophosphorylation of p38α Baoxue Ge, Hermann Gram, Franco Di Padova et al. · Science | 15 Feb 2002 | 535 |
| 3 | R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation Sylvia Braselmann et al. · Journal of Pharmacology and Experimental Therapeutics | 31 Aug 2006 | 520 |
| 4 | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention James G. Christensen, Jon Burrows, Ravi Salgia · Cancer Letters | 12 Nov 2004 | 518 |
| 5 | An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese et al. · New England Journal of Medicine | 29 Sep 2010 | 382 |
| 6 | Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials James Bruce Bussel, Donald M. Arnold, Elliot Grossbard et al. · American Journal of Hematology | 26 Apr 2018 | 369 |
| 7 | Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial Michael E. Weinblatt, Arthur Kavanaugh, Rubén Burgos‐Vargas et al. · Arthritis & Rheumatism | 30 Oct 2008 | 340 |
| 8 | Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293 T Cell–Based Systems Susan E. Swift, James B. Lorens, Philip Achacoso et al. · Current Protocols in Immunology | Jun 1999 | 320 |
| 9 | Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk Anna J. Podolanczuk, Alan H. Lazarus, Andrew R. Crow et al. · Blood | 18 Dec 2008 | 274 |
| 10 | Discovering patterns to extract protein–protein interactions from full texts Minlie Huang, Xiaoyan Zhu, Yu Hao et al. · Bioinformatics | 29 Jul 2004 | 238 |
| 11 | Toso, a Cell Surface, Specific Regulator of Fas-Induced Apoptosis in T Cells Yasumichi Hitoshi, James B. Lorens, Shinichi Kitada et al. · Immunity | Apr 1998 | 222 |
| 12 | A New Algorithm for the Evaluation of Shotgun Peptide Sequencing in Proteomics: Support Vector Machine Classification of Peptide MS/MS Spectra and SEQUEST Scores Dave C. Anderson, Weiqun Li, Donald G. Payan et al. · Journal of Proteome Research | 11 Dec 2002 | 216 |
| 13 | An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt et al. · Arthritis & Rheumatism | 27 Oct 2010 | 210 |
| 14 | Detection of programmed cell death using fluorescence energy transfer Xiang Ming Xu · Nucleic Acids Research | 15 Apr 1998 | 208 |
| 15 | Three Novel Proteins of the Syntaxin/SNAP-25 Family Martin Steegmaier, Bin Yang, Jin-San Yoo et al. · Journal of Biological Chemistry | Dec 1998 | 207 |
| 16 | TNIK, a Novel Member of the Germinal Center Kinase Family That Activates the c-Jun N-terminal Kinase Pathway and Regulates the Cytoskeleton Chong Fu, Mary Shen, Betty C. B. Huang et al. · Journal of Biological Chemistry | Oct 1999 | 195 |
| 17 | Critical Role of the Ubiquitin Ligase Activity of UHRF1, a Nuclear RING Finger Protein, in Tumor Cell Growth Yonchu Jenkins, Vadim V. Markovtsov, Wayne Lang et al. · Molecular Biology of the Cell | 30 Sep 2005 | 187 |
| 18 | Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone mice Guo‐Min Deng, Lena Liu, Frances Rena Bahjat et al. · Arthritis & Rheumatism | 10 Mar 2010 | 176 |
| 19 | An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Frances Rena Bahjat, Polly R. Pine, Andrea J. Reitsma et al. · Arthritis & Rheumatism | 25 Apr 2008 | 174 |
| 20 | Risk Factors for the Development of Malignant Melanoma—I: Review of Case‐Control Studies ROBIN D. EVANS, Alfred W. Kopf, Robert Lew et al. · The Journal of Dermatologic Surgery and Oncology | Apr 1988 | 174 |
| 21 | Targeting Syk as a treatment for allergic and autoimmune disorders Brian R. Wong, Elliott B. Grossbard, Donald G. Payan et al. · Expert Opinion on Investigational Drugs | Jul 2004 | 154 |
| 22 | An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, Robert B. Berkowitz, Elliott B. Grossbard · Journal of Allergy and Clinical Immunology | Apr 2005 | 149 |
| 23 | Identification of RIP3, a RIP-like kinase that activates apoptosis and NFκB Pei Yu, Betty C. B. Huang, Mary Shen et al. · Current Biology | May 1999 | 142 |
| 24 | Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay Susan D. Demo, Esteban S. Masuda, Alexander B. Rossi et al. · Cytometry | Aug 1999 | 127 |
| 25 | p15PAF, a novel PCNA associated factor with increased expression in tumor tissues Peiwen Yu, Betty C. B. Huang, Mary Shen et al. · Oncogene | 25 Jan 2001 | 126 |
| 26 | Activation of the PKB/AKT Pathway by ICAM-2 Omar D. Perez, Shigemi M. Kinoshita, Yasumichi Hitoshi et al. · Immunity | 2002 | 125 |
| 27 | Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program James Bruce Bussel, Donald M. Arnold, Michael A. Boxer et al. · American Journal of Hematology | 20 Feb 2019 | 122 |
| 28 | Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target Ryan M. Young, Ian R. Hardy, Raedun L. Clarke et al. · Blood | 4 Nov 2008 | 120 |
| 29 | Regulation of T Cell Receptor-induced Activation of the Ras-ERK Pathway by Diacylglycerol Kinase ζ Xiao-Ping Zhong, Ehmonie A. Hainey, Benjamin A. Olenchock et al. · Journal of Biological Chemistry | Aug 2002 | 117 |
| 30 | Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells Sandeep Kumar Krishnan, Yuang‐Taung Juang, Bhabadeb Chowdhury et al. · The Journal of Immunology | Dec 2008 | 112 |
| 31 | Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors Rajinder Singh, Esteban S. Masuda, Donald G. Payan · Journal of Medicinal Chemistry | 19 Jan 2012 | 102 |
| 32 | Amisyn, a Novel Syntaxin-binding Protein That May Regulate SNARE Complex Assembly Suzie J. Scales, Boris A. Hesser, Esteban S. Masuda et al. · Journal of Biological Chemistry | Aug 2002 | 101 |
| 33 | Inhibition of Spleen Tyrosine Kinase Prevents Mast Cell Activation and Airway Hyperresponsiveness Shigeki Matsubara, Guiming Li, Katsuyuki Takeda et al. · American Journal of Respiratory and Critical Care Medicine | 28 Sep 2005 | 99 |
| 34 | Retrovirally Delivered Random Cyclic Peptide Libraries Yield Inhibitors of Interleukin-4 Signaling in Human B Cells Todd M. Kinsella, Cara T. Ohashi, Amy Grace Harder et al. · Journal of Biological Chemistry | 27 Sep 2002 | 96 |
| 35 | Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation David J. Sweeny, Weiqun Li, Jeffrey Clough et al. · Drug Metabolism and Disposition | 7 Apr 2010 | 91 |
| 36 | The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma Alvarez Hector et al. · Cancer Biology & Therapy | 15 Nov 2010 | 90 |
| 37 | Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib Nichola Cooper, Waleed Ghanima, Quentin A. Hill et al. · Platelets | 4 Nov 2022 | 86 |
| 38 | Syk Activation in Dendritic Cells Is Essential for Airway Hyperresponsiveness and Inflammation Shigeki Matsubara, Toshiyuki Koya, Katsuyuki Takeda et al. · American Journal of Respiratory Cell and Molecular Biology | 9 Dec 2005 | 84 |
| 39 | A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis Jennifer Smith, John McDaid, Gurjeet Bhangal et al. · Journal of the American Society of Nephrology | 3 Dec 2009 | 83 |
| 40 | Identification of the Syk kinase inhibitor R112 by a human mast cell screen Alexander B. Rossi, Ellen Herlaar, Sylvia Braselmann et al. · Journal of Allergy and Clinical Immunology | 30 Jul 2006 | 82 |
| 41 | Dominant effector genetics in mammalian cells Xiang Ming Xu, Cindy Leo, Yngju Jang et al. · Nature Genetics | 2001 | 82 |
| 42 | Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients Min Jeong Kim, John McDaid, Stephen Paul McAdoo et al. · The Journal of Immunology | 6 Sep 2012 | 80 |
| 43 | Involvement of Toso in activation of monocytes, macrophages, and granulocytes Karl Sebastian Lang et al. · Proceedings of the National Academy of Sciences | 28 Jan 2013 | 79 |
| 44 | Tomosyn Binds t-SNARE Proteins via a VAMP-like Coiled Coil Esteban S. Masuda, Betty C. B. Huang, Joseph M. Fisher et al. · Neuron | Sep 1998 | 75 |
| 45 | Rab37 is a novel mast cell specific GTPase localized to secretory granules Esteban S. Masuda, Ying Luo, Chi Young et al. · FEBS Letters | 13 Mar 2000 | 75 |
| 46 | The Poxvirus p28 Virulence Factor Is an E3 Ubiquitin Ligase Jianing Huang, Qi Quan Huang, Xiulan Zhou et al. · Journal of Biological Chemistry | 21 Oct 2004 | 74 |
| 47 | Syk inhibitors as treatment for allergic rhinitis Esteban S. Masuda, Jochen Schmitz · Pulmonary Pharmacology & Therapeutics | 29 Jun 2007 | 74 |
| 48 | Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia Ralph Vincent Boccia, Nichola Cooper, Waleed Ghanima et al. · British Journal of Haematology | 23 Jul 2020 | 72 |
| 49 | Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses Shigeru Ashino, Katsuyuki Takeda, Hui Li et al. · Journal of Allergy and Clinical Immunology | 21 Dec 2013 | 71 |
| 50 | Systematic identification of regulatory proteins critical for T-cell activation Peter C. Chu, Jorge Pardo, Haoran Zhao et al. · Journal of Biology | 15 Sep 2003 | 70 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.